ARCHIVES

As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Single-Letter Mutation Found Responsible For Waldenstrom’s

December 30, 2011

Columbia Formally Names As 21st Comprehensive Center

March 9, 1979

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012

Concept Approval: NCI To Solicit “White Papers” For Technology Development Ideas

July 3, 1998

NTP Board Approves Concept Of Human Cell Assay For Genetic Toxicity

March 25, 1983

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011